Bright Minds Biosciences Management
Management criteria checks 3/4
Bright Minds Biosciences' CEO is Ian McDonald, appointed in May 2019, has a tenure of 5.75 years. directly owns 14.38% of the company’s shares, worth $40.76M. The average tenure of the management team and the board of directors is 2.6 years and 2.8 years respectively.
Key information
Ian McDonald
Chief executive officer
CA$213.2k
Total compensation
CEO salary percentage | n/a |
CEO tenure | 5.8yrs |
CEO ownership | 14.4% |
Management average tenure | 2.6yrs |
Board average tenure | 2.8yrs |
Recent management updates
Recent updates
CEO
Ian McDonald (62 yo)
5.8yrs
Tenure
CA$213,239
Compensation
Mr. Ian McDonald is Independent Director of Abpro Holdings, Inc. from November 13, 2024. Mr. McDonald is Co-Founder of Bright Minds Biosciences Inc. and serves as its Chief Executive Officer since June 06,...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 5.8yrs | CA$213.24k | 14.38% $ 40.8m | |
Chief Financial Officer | 4.8yrs | CA$120.00k | 0% $ 0 | |
Chief Science Officer & Director | 2.4yrs | CA$448.58k | 0.86% $ 2.4m | |
COO & VP of Corporate Development | 1.1yrs | no data | 0.28% $ 801.2k | |
Consultant | 2.8yrs | no data | no data | |
Chief Medical Officer | less than a year | no data | no data |
2.6yrs
Average Tenure
59yo
Average Age
Experienced Management: DRUG's management team is considered experienced (2.6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 5.8yrs | CA$213.24k | 14.38% $ 40.8m | |
Chief Science Officer & Director | 2.8yrs | CA$448.58k | 0.86% $ 2.4m | |
Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
Independent Non-Executive Director | 2yrs | CA$39.49k | 0% $ 0 | |
Independent Director | 4.4yrs | CA$17.89k | 0.066% $ 187.0k | |
Independent Director | 4.4yrs | CA$17.89k | 0.072% $ 202.8k | |
Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
Member of Scientific Advisory Board | 2.8yrs | no data | no data |
2.8yrs
Average Tenure
59yo
Average Age
Experienced Board: DRUG's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/07 00:28 |
End of Day Share Price | 2025/02/07 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bright Minds Biosciences Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Joel Beatty | Baird |
Charles Duncan | Cantor Fitzgerald & Co. |
Sepehr Manochehry | Eight Capital |